208 related articles for article (PubMed ID: 33425260)
1. The impact of Gag non-cleavage site mutations on HIV-1 viral fitness from integrative modelling and simulations.
Samsudin F; Gan SK; Bond PJ
Comput Struct Biotechnol J; 2021; 19():330-342. PubMed ID: 33425260
[TBL] [Abstract][Full Text] [Related]
2. Modeling the full length HIV-1 Gag polyprotein reveals the role of its p6 subunit in viral maturation and the effect of non-cleavage site mutations in protease drug resistance.
Su CT; Kwoh CK; Verma CS; Gan SK
J Biomol Struct Dyn; 2018 Dec; 36(16):4366-4377. PubMed ID: 29237328
[TBL] [Abstract][Full Text] [Related]
3. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites.
Zhang YM; Imamichi H; Imamichi T; Lane HC; Falloon J; Vasudevachari MB; Salzman NP
J Virol; 1997 Sep; 71(9):6662-70. PubMed ID: 9261388
[TBL] [Abstract][Full Text] [Related]
4. Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity.
van Maarseveen NM; Andersson D; Lepšík M; Fun A; Schipper PJ; de Jong D; Boucher CA; Nijhuis M
Retrovirology; 2012 Apr; 9():29. PubMed ID: 22462820
[TBL] [Abstract][Full Text] [Related]
5. Transient HIV-1 Gag-protease interactions revealed by paramagnetic NMR suggest origins of compensatory drug resistance mutations.
Deshmukh L; Louis JM; Ghirlando R; Clore GM
Proc Natl Acad Sci U S A; 2016 Nov; 113(44):12456-12461. PubMed ID: 27791180
[TBL] [Abstract][Full Text] [Related]
6. Mutational patterns in the frameshift-regulating site of HIV-1 selected by protease inhibitors.
Knops E; Brakier-Gingras L; Schülter E; Pfister H; Kaiser R; Verheyen J
Med Microbiol Immunol; 2012 May; 201(2):213-8. PubMed ID: 22200908
[TBL] [Abstract][Full Text] [Related]
7. Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss.
Dam E; Quercia R; Glass B; Descamps D; Launay O; Duval X; Kräusslich HG; Hance AJ; Clavel F;
PLoS Pathog; 2009 Mar; 5(3):e1000345. PubMed ID: 19300491
[TBL] [Abstract][Full Text] [Related]
8. Positive selection pressure introduces secondary mutations at Gag cleavage sites in human immunodeficiency virus type 1 harboring major protease resistance mutations.
Banke S; Lillemark MR; Gerstoft J; Obel N; Jørgensen LB
J Virol; 2009 Sep; 83(17):8916-24. PubMed ID: 19515784
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 protease substrate-groove: Role in substrate recognition and inhibitor resistance.
Laco GS
Biochimie; 2015 Nov; 118():90-103. PubMed ID: 26300060
[TBL] [Abstract][Full Text] [Related]
10. Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1.
Myint L; Matsuda M; Matsuda Z; Yokomaku Y; Chiba T; Okano A; Yamada K; Sugiura W
Antimicrob Agents Chemother; 2004 Feb; 48(2):444-52. PubMed ID: 14742193
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 protease-substrate coevolution in nelfinavir resistance.
Kolli M; Ozen A; Kurt-Yilmaz N; Schiffer CA
J Virol; 2014 Jul; 88(13):7145-54. PubMed ID: 24719428
[TBL] [Abstract][Full Text] [Related]
12. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.
Maguire MF; Guinea R; Griffin P; Macmanus S; Elston RC; Wolfram J; Richards N; Hanlon MH; Porter DJ; Wrin T; Parkin N; Tisdale M; Furfine E; Petropoulos C; Snowden BW; Kleim JP
J Virol; 2002 Aug; 76(15):7398-406. PubMed ID: 12097552
[TBL] [Abstract][Full Text] [Related]
13. Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance.
Kolli M; Stawiski E; Chappey C; Schiffer CA
J Virol; 2009 Nov; 83(21):11027-42. PubMed ID: 19706699
[TBL] [Abstract][Full Text] [Related]
14. Reviewing HIV-1 Gag Mutations in Protease Inhibitors Resistance: Insights for Possible Novel Gag Inhibitor Designs.
Su CT; Koh DW; Gan SK
Molecules; 2019 Sep; 24(18):. PubMed ID: 31489889
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat.
Fun A; van Maarseveen NM; Pokorná J; Maas RE; Schipper PJ; Konvalinka J; Nijhuis M
Retrovirology; 2011 Aug; 8():70. PubMed ID: 21864346
[TBL] [Abstract][Full Text] [Related]
16. Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors.
Gatanaga H; Suzuki Y; Tsang H; Yoshimura K; Kavlick MF; Nagashima K; Gorelick RJ; Mardy S; Tang C; Summers MF; Mitsuya H
J Biol Chem; 2002 Feb; 277(8):5952-61. PubMed ID: 11741936
[TBL] [Abstract][Full Text] [Related]
17. Resistance to Second-Generation HIV-1 Maturation Inhibitors.
Urano E; Timilsina U; Kaplan JA; Ablan S; Ghimire D; Pham P; Kuruppu N; Mandt R; Durell SR; Nitz TJ; Martin DE; Wild CT; Gaur R; Freed EO
J Virol; 2019 Mar; 93(6):. PubMed ID: 30567982
[TBL] [Abstract][Full Text] [Related]
18. Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors.
Aoki M; Venzon DJ; Koh Y; Aoki-Ogata H; Miyakawa T; Yoshimura K; Maeda K; Mitsuya H
J Virol; 2009 Apr; 83(7):3059-68. PubMed ID: 19176623
[TBL] [Abstract][Full Text] [Related]
19. A cleavage enzyme-cytometric bead array provides biochemical profiling of resistance mutations in HIV-1 Gag and protease.
Breuer S; Sepulveda H; Chen Y; Trotter J; Torbett BE
Biochemistry; 2011 May; 50(20):4371-81. PubMed ID: 21452835
[TBL] [Abstract][Full Text] [Related]
20. Elucidation of the Molecular Mechanism Driving Duplication of the HIV-1 PTAP Late Domain.
Martins AN; Waheed AA; Ablan SD; Huang W; Newton A; Petropoulos CJ; Brindeiro RD; Freed EO
J Virol; 2016 Jan; 90(2):768-79. PubMed ID: 26512081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
